Bender F
Z Kardiol. 1984;73 Suppl 2:101-5.
The depressing effect of calcium antagonists on sinus node and AV node function is well documented in the experimental animal and in man. Other cardiac fibers may be depolarized to a level at which the slow inward current determines the rise of the action potential and may become sensitive to calcium antagonists, thus abolishing extrasystoles or tachycardias. However, effects of the drugs on heart rate, coronary perfusion, and pre- and afterload of the left ventricle must be taken into account, which may affect the electrophysiologic basis for the dysrhythmia. The conversion rate of atrial fibrillation to sinus rhythm (n = 200) amounted to 77% when quinidine was combined with verapamil. Monotherapy of these drugs or combination of quinidine with diltiazem or pindolol did not elevate the atrial fibrillation threshold compared to quinidine/verapamil. Reduced ventricular fibrillation thresholds in the experimental animal after coronary occlusion increased significantly during the early reperfusion period after verapamil and nifedipine by cardioprotection. Due to a reduced renal clearance the bio-availability of digoxin increased with a concomitant medication of quinidine and verapamil.
钙拮抗剂对窦房结和房室结功能的抑制作用在实验动物和人体中均有充分记录。其他心脏纤维可能会去极化至缓慢内向电流决定动作电位上升的水平,并可能对钙拮抗剂变得敏感,从而消除期前收缩或心动过速。然而,必须考虑药物对心率、冠状动脉灌注以及左心室前负荷和后负荷的影响,这些可能会影响心律失常的电生理基础。当奎尼丁与维拉帕米联合使用时,心房颤动转复为窦性心律的转化率(n = 200)达77%。与奎尼丁/维拉帕米相比, 这些药物的单一疗法或奎尼丁与地尔硫䓬或吲哚洛尔联合使用均未提高心房颤动阈值。在实验动物中,冠状动脉闭塞后心室颤动阈值降低,而在维拉帕米和硝苯地平作用后的早期再灌注期,通过心脏保护作用,心室颤动阈值显著升高。由于肾清除率降低,奎尼丁和维拉帕米联合用药时,地高辛的生物利用度增加。